Park Avenue Securities LLC Sells 2,368 Shares of Hologic, Inc. $HOLX

Park Avenue Securities LLC decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 28.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,922 shares of the medical equipment provider’s stock after selling 2,368 shares during the quarter. Park Avenue Securities LLC’s holdings in Hologic were worth $386,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of HOLX. Beverly Hills Private Wealth LLC boosted its stake in shares of Hologic by 3.6% in the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock valued at $320,000 after purchasing an additional 180 shares during the last quarter. Allworth Financial LP boosted its stake in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 216 shares in the last quarter. Integrated Advisors Network LLC boosted its stake in Hologic by 5.4% during the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider’s stock worth $346,000 after acquiring an additional 289 shares in the last quarter. Townsquare Capital LLC boosted its stake in Hologic by 4.5% during the first quarter. Townsquare Capital LLC now owns 6,763 shares of the medical equipment provider’s stock worth $418,000 after acquiring an additional 293 shares in the last quarter. Finally, Empirical Finance LLC boosted its stake in Hologic by 4.0% during the first quarter. Empirical Finance LLC now owns 8,703 shares of the medical equipment provider’s stock worth $538,000 after acquiring an additional 334 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $67.49 on Wednesday. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $15.01 billion, a PE ratio of 28.00, a P/E/G ratio of 2.43 and a beta of 0.57. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a 50-day moving average price of $66.88 and a two-hundred day moving average price of $62.97.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the business earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Mizuho set a $75.00 price objective on shares of Hologic in a report on Thursday, July 31st. Argus upped their price objective on shares of Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Wall Street Zen downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Wednesday. UBS Group upped their price objective on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, July 31st. Finally, Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and increased their target price for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, Hologic presently has an average rating of “Moderate Buy” and a consensus price target of $79.38.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.